C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC): 9 pipeline candidates · ~12 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.9 months
D/E 0.40 · 21% dilution
Lead: Approved
9 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for C4 Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$405.2M
Cash
$64.7M
Quarterly Burn
$29.9M
Runway
11.9 mo
Revenue
$6.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| cemsidomide | Phase 2 |
| cetuximab | Phase 1 |
| CFT1946 | Phase 1 |
| CFT8919 | Phase 1 |
| elranatamab | Phase 1 |
| pg-033 | Phase 1 |
| tepezza | Approved |
| tepezza | Approved |
| trametinib | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
120
Total value held
$192.0M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 9,072,400 | $23.9M |
| ra capital management, l.p. | 8,000,000 | $21.0M |
| vanguard capital management llc | 7,723,704 | $20.3M |
| lynx1 capital management lp | 6,998,902 | $18.4M |
| two sigma investments, lp | 3,035,634 | $8.0M |
| wasatch advisors lp | 2,961,761 | $7.8M |
| citadel advisors llc | 2,588,615 | $6.8M |
| renaissance technologies llc | 2,461,815 | $6.5M |
| goldman sachs group inc | 2,387,378 | $6.3M |
| bank of america corp /de/ | 2,359,241 | $6.2M |
Showing top 10 of 120 institutional holders of C4 Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in C4 Therapeutics, Inc.'s pipeline?
C4 Therapeutics, Inc. (CCCC) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is C4 Therapeutics, Inc.'s lead drug candidate?
C4 Therapeutics, Inc.'s most advanced tracked candidate is cemsidomide (Phase 2) for Multiple Myeloma; Multiple Myeloma (MM).
What is C4 Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, C4 Therapeutics, Inc. has approximately 11.9 months of cash runway.
What is C4 Therapeutics, Inc.'s market capitalization?
C4 Therapeutics, Inc.'s market capitalization is approximately $405.2M.
Who is the CEO of C4 Therapeutics, Inc.?
Mr. Andrew J. Hirsch M.B.A. is the chief executive officer of C4 Therapeutics, Inc. (CCCC).
Get the full picture on C4 Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.